01
identify new opportunities
TWO Oncology reports
360 Degree Insights on Drug Development
2485 Active Cancer Drug Developers.
4725 Active Molecules in Development.
1600+ Deals & Partnering Details.
Special coverage on CAR-T, Vaccines, ADCs, Monoclonal Antibodies, Oncolytic Viruses and Small molecule Kinase Inhibitors.
Emerging Technologies like Microbiome, CRISPER, Exosomes, RNAi etc., as Cancer treatment are covered.
Report provides an extensive coverage on Oncology Drug Development and includes World’s Largest Number of Active Clinical Stage Oncology Drug Developers. (1235 Companies Profiles)
1450+ Pages provides, in-depth Analysis on
- GLOBAL 1235 CLINICAL STAGE ONCOLOGY DRUG DEVELOPERS.
- 2730 CANCER TARGETING MOLECULES IN DEVELOPMENT.
- EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
- ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
- INDIVIDUAL COMPANY FUNDING STATUS
Report opens an immense opportunities to New Business Development.
Explore More
Single Source Solution to Reach-out and connect World’s Largest Number of Active Early Stage Oncology Drug Developers. (1250 Companies).
945 Pages Report contains in-depth Analysis on
- 1250 ACTIVE COMPANIES PROFILE
- 1200+ CANCER TARGETING MOLECULES IN DEVELOPMENT.
- EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
- ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
- INDIVIDUAL COMPANY FUNDING STATUS, and much more.Â
Report opens an immense opportunities to New Business Development.
Explore More
